← Leaderboards
Paul Mathew
Tufts Medical Center
$2,410,363
Attributed
$2,410,363
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $498K · FY2020–24$500K$375K$250K$125K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,410,363 · 1
By mechanism
R01$2,410,363 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Adhesives”
- Brian Hess · Revbio, Inc.$10,684,188
- Gary Fanger · Rise Therapeutics, Llc$5,693,496
- Alice E White · Trustees Of Boston University$5,580,231
- Brendon M Baker · Trustees Of Boston University$5,580,231
- Steve Lim · University Of South Alabama$4,942,628
- Patrick R Secor · University Of Montana$4,394,600
Research focus
AdhesivesCharacteristicsAffectAfricanAdvanced DiseaseAnimal ModelAnoikisAntibodiesAntibody TherapyAutopsyAndrogen ReceptorBehaviorBenignBiobankBiological MarkersBispecific AntibodiesBoneBone MarrowBreastCastrationCaucasiansCell CommunicationCessation Of LifeChemotaxis
Grant awards (5)
Control of lethal prostate cancer with a bispecific av and a5b1 integrin antibody$497,137
R01 · FY2024 · CA · contact PI
Control of lethal prostate cancer with a bispecific av and a5b1 integrin antibody$497,984
R01 · FY2023 · CA · contact PI
Control of lethal prostate cancer with a bispecific av and a5b1 integrin antibody$467,360
R01 · FY2022 · CA · contact PI
Control of lethal prostate cancer with a bispecific av and a5b1 integrin antibody$473,941
R01 · FY2021 · CA · contact PI
Control of lethal prostate cancer with a bispecific av and a5b1 integrin antibody$473,941
R01 · FY2020 · CA · contact PI